key: cord-0696668-1t78tt1s
authors: Zhou, Runhong; Kai-Wang To, Kelvin; Wong, Yik-Chun; Liu, Li; Zhou, Biao; Li, Xin; Huang, Haode; Mo, Yufei; Luk, Tsz-Yat; Tsz-Kan Lau, Thomas; Yeung, Pauline; Chan, Wai-Ming; Ka-Lun Wu, Alan; Lung, Kwok-Cheung; Tak-Yin Tsang, Owen; Leung, Wai-Shing; Fan-Ngai Hung, Ivan; Yuen, Kwok-Yung; Chen, Zhiwei
title: Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses
date: 2020-08-04
journal: Immunity
DOI: 10.1016/j.immuni.2020.07.026
sha: dcae13bf7f7da93d9dd13e71b3e6c1f8d88427a7
doc_id: 696668
cord_uid: 1t78tt1s

Summary The SARS-CoV-2 pandemic has resulted in millions of infections yet the role of host immune responses in early COVID-19 pathogenesis remains unclear. By investigating 17 acute and 24 convalescent patients, we found that acute SARS-CoV-2 infection resulted in broad immune cell reduction including T, NK, monocyte and dendritic cell (DC). DCs were significantly reduced with functional impairment, and cDC:pDC ratios were increased among acute severe patients. Besides lymphocytopenia, although neutralizing antibodies were rapidly and abundantly generated in patients, there were delayed receptor binding domain (RBD)- and nucleocapsid protein (NP)-specific T cell responses during the first 3 weeks post symptoms onset. Moreover, acute RBD- and NP-specific T cell responses included relatively more CD4 T cells than CD8 T cells. Our findings provided evidence that impaired DCs, together with timely inverted strong antibody but weak CD8 T cell responses, may contribute to acute COVID-19 pathogenesis and have implications for vaccine development.

In December 2019, the Coronavirus disease 2019 (COVID-19) outbreak was discovered 56 among a group of pneumonia patients mainly associated with a seafood market in Wuhan city, 57

China (Zhu et al., 2020) . The pandemic was suspected to be zoonotic and to have originated 58 from a novel beta-coronavirus (CoV) that is now officially named as SARS-CoV-2 (Qian et 59 al., 2020; Zhu et al., 2020) . SARS-CoV-2 is similar to bat SARS-related coronaviruses with 60 96% genomic identity, but it is relatively distinct from SARS-CoV that only has 79.5% To further evaluate the impact of disease severity on patients' immune cell profiles at the  222   acute stage of SARS-CoV-2 infection, we divided the AP group into mild and severe patients  223 for comparison. Interestingly, the frequency of M-MDSCs was significantly higher in severe 224 patients than that of mild ones ( Figure 4A ). There were no significant differences for other 225 immune cell types including T, B, NK, DC and monocytes between mild and severe patients. 226

Moreover, there were no significant differences for expression of Ki67, PD-1 and 227 CD38 + HLA-DR in both CD4 and CD8 T cells ( Figure S5 ). When DC subsets were further 228 analyzed, however, there was a significant increase of the cDC:pDC ratio in severe patients 229 than that in mild ones ( Figure 4B , top panel) although significant differences were not found 230 for the frequencies of cDC and pDC. In addition, there were no significant differences in 231 HLA-DR, CD86 and CCR2 expression on cDC between mild and severe patients ( Figure 4B , 232 bottom panel). These findings suggested that acute SARS-CoV-2 infection results in more 233 significant changes in cDC:pDC ratios and the increase of M-MDSCs among severe patients. 234

High cDC:pDC ratios of about 50-fold may serve as a potential biomarker of severe sickness. 235 236

Upon viral entry, earlier development of antigen-specific T cells and subsequent production 238 of neutralizing antibodies (NAb) are classical adaptive immune responses for effective 239 control of infection and elimination of pathogens (Chaplin, 2010) . To further study specific 240 immunity in AP, we developed ELISA and pseudovirus-based neutralization assays to 241 measure antibody responses, as well as ELISPOT to measure cell-mediated immune 242 responses. In the first week after symptoms onset, specific RBD IgG responses were found 243 in 4/7 mild AP (P2, P3, P4 and P7) by ELISA. Three of them developed high NAb titers but 244 low NP-specific T cell responses, whereas only 2 of them had weak RBD-specific T cells 245 ( Figure 5A ). Only P4 had NP-specific T cells with > 500 spots/million PBMC. In the 246 second week after symptoms onset, 8/8 AP, including 4 mild and 4 severe cases, developed 247 both RBD IgG and Nab responses. Importantly, however, 4/4 severe patients (P8, P10, P11 248 and P13) did not develop measurable T cell responses against NP or RBD. In contrast, two 249 mild followed-up cases P3 and P4 displayed increased NP-but not RBD-specific T cells 250 while P3 developed NAb response at this stage. Another mild case P12 had RBD IgG and 251

NAb responses but weak NP-and RBD-specific T cell responses (< 100 spots/million 252 PBMC). In the third week and beyond, 4 AP were newly recruited including 2 severe cases 253 (P16 and P17) and 2 mild cases (P14 and P15) whereas the rest were followed-up patients. 254

During this stage, all AP had RBD IgG and NAb responses. Most AP also developed 255 increased NP-specific T cell responses except for the mild P14 and the severe P16 who did  256   not have measurable T cell responses against NP and RBD. Notably, 3/5 followed-up  257   patients including P7, P8 and P10 developed RBD-specific but weak T cell responses. Our  258 results, therefore, demonstrated that the overall frequencies of RBD IgG and NAb responses 259 in AP reached 100% (8/8) by the second week after symptom onset, whereas only 50% (4/8) 260 and 25% (2/8) were found for NP-and RBD-specific T cell responses, respectively ( Figure  261 5B, left). When the AP group was divided to compare mild versus severe cases, 4/4 and 2/4 262 mild AP had NP-and RBD-specific T cell responses ( Figure 5B and NP-specific T cell responses, respectively ( Figure 6A ). Moreover, when RBD peptide 285 pool and RBD protein were compared using the same ELISPOT, consistent responses were 286 observed with a significantly positive correlation ( Figure S7 ). Based on availability of 287 isolated cells, we also determined specific T cell responses in CD4 and CD8 subsets by ICS 288 in 3 AP and 13 CP. Significantly higher frequencies of T cell responses were found in CD4 289 than in CD8 T cells against both RBD and NP ( Figure 6B ). Moreover, consistent with the 290 ELISPOT results, the frequencies of NP-specific T cell responses were higher than RBD-291 specific T cell responses, which is similar to a recent study of CP subjects (Ni et al., 2020) . 292

Interestingly, the majority of NP-and RBD-specific CD4 T cells tended to have an effector 293 memory (EM) phenotype ( Figure 6C ). NP-and RBD-specific but weaker CD8 T cells also 294 exhibited the effector memory (EM) phenotype ( Figure S8A ). Interestingly, when all 51 295 samples from 17 AP and 23 CP were analysed together, there was a strong positive 296 correlation between RBD IgG and NAb responses ( Figure S8B ) as well as between RBD-297 specific T cell response and NAb titer ( Figure S8C ). The development of NAb, therefore, 298 may still be correlated with the induction of RBD-specific T cells responses. In contrast, the 299 correlation between NP RBD-specific T cell response and NAb titer did not reach statistical 300 significance ( Figure S8D ). Our results indicated that timely inverted strong antibody but DCs neither produced anti-viral cytokines nor matured to perform direct antigen presentation 310 to activate T cells (Law et al., 2005) .

In NHP, we showed that mucosal 311 monocytes/macrophages sequestered SARS-CoV virions in intracellular vesicles together 312 with infected Langerhans cells (Liu et al., 2016) . They then migrated into the tonsils and/or 313 draining lymph nodes, all within 2 days of infection. In lymphoid tissues, viral RNA and 314 proteins were detected in infected monocytes upon differentiation into DCs within 3 days. 315 Therefore, spatiotemporal interactions of SARS-CoV, monocytes/macrophages, and the DC 316 network in mucosal tissues provide a mechanism for the virus to escape host mucosal innate 317 immunity and disseminate systemically (Liu et al., 2016) . Among SARS patients, the 318 frequency of peripheral DC subsets significantly dropped after symptoms onset, mainly 319 attributed to a large dose of steroid administration (Zhang et al., 2004) . In this study, 320 although few of our AP COVID-19 patients received even low dose steroid treatment, the 321 frequency and functionality of peripheral DC subsets still significantly and rapidly reduced 322 upon symptoms onset. On the one hand, pDC is the major potent type-I interferon producer 323 upon viral infection. Therefore, the significant loss of pDC, together with NK cells reduction 324 among severe cases may lead to immediate abolishment of innate immunity against SARS-325

CoV-2 infection. To CoV and SARS-CoV-2, the R441 residue remains conserved in both and allows the induction 358 of RBD-specific NAbs. However, it is surprising that our AP subjects did not develop strong 359

This might be partly due to diminished DC function as mentioned above, or due to 7 amino 362 acid differences (underlined) in the predicted immunodominant T cell epitope 435-363 NYNYLYRLFRKSNLKPF-451 in SARS-CoV-2. We also observed that 39% CP subjects 364 did not develop measurable RBD-specific T cell responses. It is possible that lacking RBD-365 specific T cell responses might be one of the potential mechanisms allowing SARS-CoV-2 to 366 evade immune control and results in prolonged viral shedding as compared with SARS-CoV. different from what was seen in SARS patients . In this study, we found that 376 besides the overall loss of T cell functionality during acute SARS-CoV-2 infection, both 377 RBD-and NP-specific T cells were likely dominated by CD4 T cells. Since we were not able 378 to obtain T cells from more severely ill patients in ICU for comparison, we could not 379 establish the role of antigen-specific CD4 T cells in promoting COVID-19 disease severity. 380

However, we found that 3/6 severe AP cases (P11, P13 and P16) had neither measurable CD4 381 nor CD8 T cell responses in contrast to their high amounts of potent NAb. In particular, 382 although there is not a statistically significant difference in overall T cell responses between 383 mild versus severe acute cases, the delayed RBD-and NP-specific T cell responses within 384 first two weeks after symptoms onset might impact disease severity. It should be noted that 385 initial T cell immune responses are highly variable among AP but they tend to improve over 386 time. Overall, the unusual timely reverted NAb and T cell responses in acute patients might 387 contribute to COVID-19 pathogenesis. In support of this notion, we and others have 388 previously reported that deceased SARS patients had faster development of NAb than 389 convalescent patients did (Ho et al., 2005; Zhang et al., 2006) . Moreover, COVID-19 390 patients with higher amounts of anti-S, anti-N IgG and IgM correlate with worse clinical 391 outcomes than patients with older age (Jiang et al., 2020) . A recent preprint study indicated 392 that SARS-CoV-2 NAb responses are more robust in patients with severe disease (Wang et 393 al., 2020b) , which agrees with our recent finding that severe AP subjects in ICU displayed 394 significantly higher amounts of RBD IgG and NAb (Liu et al., 2020) . In this study, although 395 our overall AP and CP data indicated that the development of NAb may be correlated with 396 the induction of RBD-specific T cells responses, which likely supports the notion that the 397 production of NAbs by plasma B cells requires the priming of viral protein specific CD4 T 398 cells (Grifoni, 2020; Mitchison, 2004) , the underlying mechanism of faster NAb and delayed 399 RBD-specific CD4 T cells response during acute infection remains to be investigated. responses, peripheral SARS-CoV-2-specific CD8 + and CD4 + T cells were identified in ~70% 405 and 100% of COVID-19 CP, respectively, using the T cell receptor-dependent activation 406 induced marker (AIM) assay (Grifoni, 2020) . Since this assay did not measure the antigen-407 specific intracellular cytokine production, whether or not the responses were overestimated 408 remains to be further determined. Here, we demonstrated consistently that while 100% 409 Figure 2B were stimulated with or without the proinflammatory cytokine 502 cocktail (stimuli) for 24 hours, followed by γ-irradiation, and then co-culturing with CFSE-503 labelled allogeneic T cells from a HD for 5 days. Proliferation of CD4 and CD8 T cells was 504 determined by % CFSE low and analysed by flow cytometry. Each symbol represents an 505 individual donor and the mean of each group are shown. Statistics were generated using one-506 way ANOVA followed by Tukey's multiple comparisons test Mann-Whitney test and 2-507 tailed Student's t test. *p<0.05; **p<0.01, ***p<0.001. 508

See also Figure S2 , S3 and Table S1, S2. 509 510

Fresh PBMCs from 13 AP and 9 CP were collected at a median of 9 (range, 1-20 days) and 513 31 days (range, 23-54 days) after symptoms onset, respectively. Phenotypes of RBD and NP-specific CD4 T cells were defined using CD45RA and CCR7 584 markers (left). Averaged frequencies of each subset of IFN-γ + cells were shown (right). 585

Statistics were generated using 2-tailed Student's t test. *p<0.05. 586

See also Figure S7 , S8 and Table S1, S3. 587 The study did not generate any unique datasets or codes. remained hospitalized during study, were recruited in the acute patient (AP) group. Blood 618 samples were collected at the median 13.5 days after symptom onset (range, 1-42 days). A 619 total of 28 blood samples were collected from the AP cohort, of which 21 samples were 620 collected within 21 days after symptom onset and 7 samples were collected at least 21 days 621 after symptom onset. Among the convalescent patients (CP) who received treatment and were 622 subsequently discharged from the hospital, a total of 29 blood samples from 3 severe and 26 623 mild patients were collected at the median 30 days (range, 21-54 days) after symptoms onset. 624

Patient information of the overall cohort, including age, sex, and health status, was shown in 625 Table 1 . A comparison of patient information between acute patients and convalescent 626 patients was shown in Table S1 . Healthy human blood buffy coats were obtained from the 627 To measure T cell activation, PBMCs were stimulated with the commercially available cell 685 activation cocktail (Biolegend) containing phorbol 12-myristate-13-acetate (PMA) and 686 ionomycin in the presence of brefeldin A (BFA, 7.5 µg/mL, Sigma-Aldrich) for 6 h. For 687 COVID-19-specific T cell responses, PBMCs were stimulated with 1 µg/mL COVID-19 688 RBD peptide pool (15-mer overlapping by 11, spanning the whole RBD sequence at Spike 306-689 543 ) or 5 µg/mL purified nucleocapsid (NP) protein in the presence of 0.5 µg/mL anti-CD28 690 and anti-CD49d mAbs (BD Bioscience). Cells were incubated at 37℃ overnight and BFA 691 was added at 2 hours post incubation, as previously described (Li et al., 2008a) . 692 PMA/ionomycin stimulation was included as positive control. After overnight incubation, 693 cells were washed with staining buffer (PBS containing 2% FBS) and stained with mAbs 694 against surface markers. For intracellular staining, cells were fixed and permeabilized with 695 BD Cytofix/Cytoperm (BD Biosciences) prior to staining with the mAbs against cytokines 696 (Table S2) . Results were considered positive when there was at least a 2-fold increase above 697 the background of HD. 698

Frozen PBMCs were rested overnight at 37℃ with 5% CO 2 after thawing. Cells were then 701 seeded into the anti-human IFN-γ mAb pre-coated 96-well plate at 200,000 cells/well. The 702 COVID-19 RBD peptide pool using the optimal concentration of 1 µg/mL (Grifoni, 2020) were tested using a one-way analysis of variance (ANOVA) followed by Tukey's multiple 757 comparisons test. Significant differences between two groups were performed using the 2-758 tailed Student's t test. P < 0.05 was considered statistically significant. 

CoV-2 Drives Development of COVID-19

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a 775 patient with atypical pneumonia after visiting Wuhan

Improved Molecular Diagnosis of COVID-19 by the 778 Novel, Highly Sensitive and Specific COVID-19

Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

Virus-782 specific memory CD8 T cells provide substantial protection from lethal severe acute 783 respiratory syndrome coronavirus infection

Overview of the immune response

Response of memory CD8+ T cells to severe acute respiratory 787 syndrome (SARS) coronavirus in recovered SARS patients and healthy individuals

Clinical progression of patients with COVID-19 in Shanghai

Epidemiological and clinical characteristics of 99 cases of 2019 novel 794 coronavirus pneumonia in Wuhan, China: a descriptive study

CoViD-19 Immunopathology and 796 Immunotherapy

Comparative replication and immune activation profiles of SARS-799

CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the 800 pathogenesis of COVID-19

Predictors of Mortality for Patients with COVID-19 Pneumonia 803 Caused by SARS-CoV-2: A Prospective Cohort Study

Plasmacytoid dendritic cells and type I 805 IFN: 50 years of convergent history

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 810 disease and unexposed individuals

A tumor-associated 813 glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells

Neutralizing antibody response and SARS severity

First Case of 2019 Novel Coronavirus in 820 the United States

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 823 China. Lancet

Triple combination of interferon beta-1b, lopinavir-ritonavir, and 826 ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, 827 randomised

Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents 830 using a proteome microarray

Human CD141(+) (BDCA-3)(+) 833 dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell 834 antigens

Chemokine up-regulation in SARS-coronavirus-infected, 837 monocyte-derived human dendritic cells

T cell responses to whole SARS coronavirus in humans

T cell responses to whole SARS 843 coronavirus in humans

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-846 19

High neutralizing antibody titer in intensive care unit 849 patients with COVID-19

Anti-spike IgG causes severe acute lung injury by skewing macrophage 852 responses during acute SARS-CoV infection

Spatiotemporal interplay of severe acute respiratory syndrome 855 coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques

Identification of a novel conserved 858 HLA-A*0201-restricted epitope from the spike protein of SARS-CoV

T-cell-B-cell cooperation

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in 862 COVID-19 Convalescent Individuals

Transmission of 2019-nCoV Infection 869 from an Asymptomatic Contact in Germany

Rapid induction of 872 tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with 873 mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells

Coronavirus During the Acute and Convalescent Phases of Human Infection

Viral Kinetics and Antibody Responses in Patients with COVID-19

Longitudinally profiling neutralizing antibody response to SARS 884 coronavirus with pseudotypes

Temporal profiles of viral load in posterior 887 oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-888 2: an observational cohort study

Severe acute 890 respiratory syndrome and the innate immune responses: modulation of effector cell function 891 without productive infection

Normal human CD4(+) 893 memory T cells display broad heterogeneity in their activation threshold for cytokine 894 synthesis

Receptor recognition by novel 896 coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel 900 Coronavirus-Infected Pneumonia in Wuhan

SARS-CoV-2 Neutralizing Antibody Responses Are More 903

T-cell epitopes in severe acute respiratory 906 syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in 907 patients who recover from SARS

Genome Composition and Divergence of the Novel Coronavirus 910 (2019-nCoV) Originating in China

Tandem bispecific neutralizing antibody eliminates HIV-1 infection in 913 humanized mice